KR100964411B1 - 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜 - Google Patents

생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜 Download PDF

Info

Publication number
KR100964411B1
KR100964411B1 KR1020047011171A KR20047011171A KR100964411B1 KR 100964411 B1 KR100964411 B1 KR 100964411B1 KR 1020047011171 A KR1020047011171 A KR 1020047011171A KR 20047011171 A KR20047011171 A KR 20047011171A KR 100964411 B1 KR100964411 B1 KR 100964411B1
Authority
KR
South Korea
Prior art keywords
alkyl
substituted
formula
group
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047011171A
Other languages
English (en)
Korean (ko)
Other versions
KR20040081463A (ko
Inventor
코청 린
알. 블레이크 페핀스키이
링 링 첸
도나 엠. 헤스
에드워드 와이. 린
러셀 씨. 피터
다렌 피. 베이커
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20040081463A publication Critical patent/KR20040081463A/ko
Application granted granted Critical
Publication of KR100964411B1 publication Critical patent/KR100964411B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C08G65/48—Polymers modified by chemical after-treatment
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
KR1020047011171A 2002-01-18 2003-01-17 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜 Expired - Lifetime KR100964411B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34991702P 2002-01-18 2002-01-18
US60/349,917 2002-01-18
PCT/US2003/001559 WO2003061577A2 (en) 2002-01-18 2003-01-17 Polyalkylene glycol with moiety for conjugating biologically active compound

Publications (2)

Publication Number Publication Date
KR20040081463A KR20040081463A (ko) 2004-09-21
KR100964411B1 true KR100964411B1 (ko) 2010-06-15

Family

ID=27613339

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047011171A Expired - Lifetime KR100964411B1 (ko) 2002-01-18 2003-01-17 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜

Country Status (35)

Country Link
US (2) US8017733B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (3) EP3025726B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (5) JP2005526151A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100964411B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (2) CN101700401B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2003210564B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2016C040I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG66525B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0306993B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (4) CA2840490C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY2016027I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ2004877A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (2) DK1476181T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (2) EA011829B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05509B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES2566797T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR16C0034I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GE (2) GEP20074024B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (4) HUE028163T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL163006A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IS (1) IS2989B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU93162I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (2) ME00239B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA04006855A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300826I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO339857B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ534708A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (2) PL397261A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT3025726T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55578B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (2) SI3025726T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK3102004A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA82184C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2003061577A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200406555B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150246097A9 (en) * 2002-01-18 2015-09-03 Biogen Idec Ma Inc. Polyalkylene Polymer Compounds and Uses Thereof
GEP20074024B (en) * 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
EP1546235B1 (en) 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
EP1628618A4 (en) * 2002-12-26 2009-09-09 Mountain View Pharmaceuticals POLYMER CONJUGATES OF CYTOKINES, CHEMOKINS, GROWTH FACTORS, POLYPEPTIDE HORMONES AND ANTAGONISTS THEREOF WITH PRESERVED RECEPTOR BINDING ACTIVITY
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US7432331B2 (en) 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
ATE444984T1 (de) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
JP5628467B2 (ja) 2003-06-26 2014-11-19 シヴィダ・ユーエス・インコーポレイテッドＰｓｉｖｉｄａ Ｕｓ， Ｉｎｃ． 生体分解性徐放性ドラッグデリバリーシステム
CA2530136C (en) 2003-06-26 2012-10-16 Control Delivery Systems, Inc. In-situ gelling drug delivery system
US20090312344A1 (en) * 2004-05-31 2009-12-17 Mohammad Salman Arylpiperazine derivatives as adrenergic receptor antagonists
CN101111267B (zh) 2004-12-21 2012-12-05 尼克塔治疗公司 稳定的聚合物巯基试剂
WO2006130553A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors
WO2007008563A2 (en) * 2005-07-08 2007-01-18 Elan Pharmaceuticals, Inc. Preparation of pegylated conjugates of vla-4 antagonists via a mitsunobu' s reaction
AU2007253717A1 (en) * 2006-05-22 2007-11-29 Elan Pharmaceuticals, Inc. Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds
US20100222546A1 (en) * 2006-11-28 2010-09-02 David Crich Methods for the preparation of functionalized peptides, proteins and carbohydrates and their conjugates
US20090017004A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery systems containing an aromatic allylic acid
CA2693616A1 (en) * 2007-07-11 2009-01-15 Enzon Pharmaceuticals, Inc. Polymeric drug delivery system containing a multi-substituted aromatic moiety
CL2008002399A1 (es) * 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
US20110165121A1 (en) * 2008-06-05 2011-07-07 Hausman Diana F Use of pegylated type iii interferons for the treatment of hepatitis c
KR101533757B1 (ko) * 2008-07-31 2015-07-03 파마이센시아 코퍼레이션 펩티드-중합체 접합체
GB0823309D0 (en) * 2008-12-19 2009-01-28 Univ Bath Functionalising reagents and their uses
WO2010140350A1 (ja) 2009-06-02 2010-12-09 パナソニック株式会社 ダウンミックス装置、符号化装置、及びこれらの方法
UA109646C2 (uk) * 2009-12-10 2015-09-25 Терапевтичне застосування кон'югатів білка з полімером
US20130225789A1 (en) * 2012-02-29 2013-08-29 Yi Sun Polyethylene Glycol Having Hetero Multiple Functional Groups
US8993614B2 (en) 2012-03-15 2015-03-31 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
KR101475630B1 (ko) * 2013-05-31 2014-12-22 동국대학교 산학협력단 포도근 추출물 또는 이의 분획물을 유효성분으로 포함하는 c형 간염의 예방 또는 치료용 조성물
US11759500B2 (en) * 2014-07-24 2023-09-19 Abion Inc. PEGylated interferon-beta variant
HRP20201725T1 (hr) 2014-08-19 2021-03-05 Biogen Ma Inc. Postupak pegilacije
GB201419108D0 (en) 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
TWI737583B (zh) 2014-11-06 2021-09-01 藥華醫藥股份有限公司 用於長效型干擾素之劑量方案
EP3421442B1 (en) * 2017-06-28 2020-08-05 Construction Research & Technology GmbH Dispersant for inorganic particles
US11472894B2 (en) 2018-07-23 2022-10-18 Carnegie Mellon University Enzyme-assisted ATRP procedures
WO2020028715A1 (en) 2018-08-01 2020-02-06 Russell Alan J Amino-reactive positively charged atrp initiators that maintain their positive charge during synthesis of biomacro-initiators
CN109232898A (zh) * 2018-08-02 2019-01-18 张玲 一种具有抗凝血功能的聚酰亚胺新材料的制备方法
CN111534458B (zh) * 2020-04-13 2022-01-14 浙江工业大学 无色杆菌tbc-1及其在降解1,3,6,8-四溴咔唑中的应用
CN113716982B (zh) * 2021-08-24 2022-05-06 重庆云瑞肥业有限公司 一种食品垃圾回收用发酵制肥装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
EP0082481B2 (en) 1981-12-23 1990-09-12 Schering Corporation Stabilised alpha-interferon formulations and their preparation
WO1985003934A1 (en) * 1984-03-06 1985-09-12 Takeda Chemical Industries, Ltd. Chemically modified protein and process for its preparation
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
WO1987000056A1 (en) 1985-06-26 1987-01-15 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
JP2514950B2 (ja) 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4894226A (en) 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5286637A (en) * 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
WO1993012145A1 (en) 1991-12-19 1993-06-24 Baylor College Of Medicine Pva or peg conjugates of peptides for epitope-specific immunosuppression
ZA933926B (en) 1992-06-17 1994-01-03 Amgen Inc Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5874075A (en) 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
WO1995013090A1 (en) 1993-11-10 1995-05-18 Enzon, Inc. Improved interferon polymer conjugates
US5951974A (en) 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
EP0796324A1 (en) 1994-12-07 1997-09-24 Novo Nordisk A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
NZ322686A (en) * 1995-10-19 2000-01-28 Univ Washington Discrete-length polyethene glycols
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US5747639A (en) 1996-03-06 1998-05-05 Amgen Boulder Inc. Use of hydrophobic interaction chromatography to purify polyethylene glycols
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
EP0975809A4 (en) 1997-03-05 2002-10-30 Univ Washington EXAMINATION PROCEDURE FOR DETECTING AGENTS FOR SELECTIVE INHIBITION OF HCV REPLICATION
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
EP1037649B1 (en) * 1997-12-17 2009-09-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
US5981709A (en) 1997-12-19 1999-11-09 Enzon, Inc. α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US5965119A (en) 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
DK1411075T3 (da) * 1998-03-12 2008-10-27 Nektar Therapeutics Al Corp Fremgangsmåde til fremstilling af polymerkonjugater
SI1075281T1 (en) 1998-04-28 2005-02-28 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
LT2599503T (lt) * 1998-10-16 2017-06-26 Biogen Ma Inc. Interferono beta-1a polimero konjugatai ir jų panaudojimas
WO2001000246A2 (en) * 1999-06-11 2001-01-04 Shearwater Corporation Hydrogels derived from chitosan and poly(ethylene glycol)
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
AU6687000A (en) 1999-08-27 2001-03-26 Maxygen Aps New interferon beta-like molecules
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
WO2001046291A1 (en) * 1999-12-22 2001-06-28 Shearwater Corporation Sterically hindered derivatives of water soluble polymers
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
WO2002026265A2 (en) * 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
TW593427B (en) * 2000-12-18 2004-06-21 Nektar Therapeutics Al Corp Synthesis of high molecular weight non-peptidic polymer derivatives
US7053150B2 (en) 2000-12-18 2006-05-30 Nektar Therapeutics Al, Corporation Segmented polymers and their conjugates
UA100967C2 (ru) * 2001-02-01 2013-02-25 Байоджен Айдек Ма Інк. Конъюгаты нейбластина с полимерами и способы их применения
YU48703A (sh) 2001-02-27 2006-05-25 Maxygen Aps Novi interferonu beta-slični molekuli
US7009033B2 (en) 2001-07-02 2006-03-07 Polymer Source Inc. Heterofunctional polyethylene glycol and polyethylene oxide, process for their manufacture
EP2939696B1 (en) * 2001-10-18 2016-03-09 Nektar Therapeutics Polymer conjugates of opioid antagonists
BR0214451A (pt) * 2001-11-20 2006-05-30 Pharmacia Corp conjugados do hormÈnio do crescimento humano quimicamente modificado
US6916962B2 (en) 2001-12-11 2005-07-12 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
KR100488351B1 (ko) 2001-12-11 2005-05-11 선바이오(주) 신규한 폴리에틸렌글리콜-프로피온알데히드 유도체
US6956135B2 (en) 2001-12-11 2005-10-18 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
US7041855B2 (en) 2001-12-11 2006-05-09 Sun Bio, Inc. Monofunctional polyethylene glycol aldehydes
WO2003049699A2 (en) * 2001-12-11 2003-06-19 Sun Bio, Inc. Novel monofunctional polyethylene glycol aldehydes
GEP20074024B (en) * 2002-01-18 2007-01-10 Biogen Idec Inc Polyalkylene glycol comprising a radical for conjugation of biologically active compound
EP1546235B1 (en) 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
WO2004060299A2 (en) 2002-12-26 2004-07-22 Mountain View Pharmaceuticals, Inc. Polymer conjugates of interferon-beta with enhanced biological potency
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5990237A (en) 1997-05-21 1999-11-23 Shearwater Polymers, Inc. Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines

Also Published As

Publication number Publication date
HK1224185A1 (en) 2017-08-18
SI3025726T1 (sl) 2020-03-31
CA2753899C (en) 2014-03-25
ME00239B (me) 2011-05-10
HU230473B1 (hu) 2016-07-28
IS7353A (is) 2004-07-15
GEP20064024B (en) 2007-01-10
CY2016027I2 (el) 2017-06-28
BRPI0306993B1 (pt) 2020-03-10
WO2003061577A2 (en) 2003-07-31
HUE047557T2 (hu) 2020-04-28
HUE028163T2 (en) 2016-11-28
ES2566797T3 (es) 2016-04-15
EA200400962A1 (ru) 2005-06-30
HK1072721A1 (zh) 2005-09-09
EE05509B1 (et) 2012-02-15
NO344612B1 (no) 2020-02-10
JP6030717B2 (ja) 2016-11-24
CN1630530A (zh) 2005-06-22
BRPI0306993B8 (pt) 2021-05-25
UA82184C2 (uk) 2008-03-25
NO20151082A1 (no) 2015-08-26
EA200701386A1 (ru) 2007-10-26
RS63504A (en) 2007-02-05
CY2016027I1 (el) 2017-06-28
NO20043422L (no) 2004-10-11
JP5275125B2 (ja) 2013-08-28
CA2753899A1 (en) 2003-07-31
PL213322B1 (pl) 2013-02-28
CA2840490C (en) 2017-02-28
ZA200406555B (en) 2005-11-30
HUS1600035I1 (hu) 2016-10-28
CA2952488A1 (en) 2003-07-31
WO2003061577A8 (en) 2008-11-20
HUP0500457A2 (hu) 2005-08-29
GEP20074024B (en) 2007-01-10
US20050107277A1 (en) 2005-05-19
NL300826I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2017-03-16
FR16C0034I2 (fr) 2019-10-04
FR16C0034I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2016-09-23
EA009783B1 (ru) 2008-04-28
EP1476181A2 (en) 2004-11-17
US20120014916A1 (en) 2012-01-19
CN101700401B (zh) 2013-08-14
EP1476181B1 (en) 2016-03-23
IL163006A (en) 2011-01-31
CA2952488C (en) 2019-05-07
DK1476181T3 (en) 2016-05-23
CY1122841T1 (el) 2021-10-29
JP2005526151A (ja) 2005-09-02
AU2003210564B2 (en) 2008-10-23
EA011829B1 (ru) 2009-06-30
US8524660B2 (en) 2013-09-03
PT3025726T (pt) 2020-01-09
CN101700401A (zh) 2010-05-05
EE200400105A (et) 2004-12-15
RS55578B1 (sr) 2017-06-30
SI1476181T1 (sl) 2016-10-28
HK1143553A1 (en) 2011-01-07
IS2989B (is) 2017-11-15
BR0306993A (pt) 2005-09-06
CA2840490A1 (en) 2003-07-31
SK3102004A3 (sk) 2005-01-03
PL397261A1 (pl) 2012-03-26
CA2473526A1 (en) 2003-07-31
BE2016C040I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2022-05-17
PL372728A1 (en) 2005-08-08
MEP35608A (hr) 2011-02-10
DK3025726T3 (da) 2019-12-09
CZ2004877A3 (cs) 2004-12-15
NO2017013I2 (no) 2018-08-20
CA2473526C (en) 2013-10-22
BG108839A (bg) 2005-04-30
ES2774801T3 (es) 2020-07-22
BG66525B1 (bg) 2016-04-28
JP2013136756A (ja) 2013-07-11
JP2009235409A (ja) 2009-10-15
EP1476181A4 (en) 2008-11-19
NO339857B1 (no) 2017-02-06
NO2017013I1 (no) 2017-04-10
LU93162I2 (fr) 2016-10-03
EP3025726B1 (en) 2019-11-20
JP2016014022A (ja) 2016-01-28
MXPA04006855A (es) 2005-04-19
KR20040081463A (ko) 2004-09-21
US8017733B2 (en) 2011-09-13
NZ534708A (en) 2007-05-31
EP3669887A1 (en) 2020-06-24
WO2003061577A3 (en) 2003-10-02
EP3025726A1 (en) 2016-06-01
HUP0500457A3 (en) 2012-09-28
JP2012255156A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
KR100964411B1 (ko) 생물학적 활성 화합물과 컨쥬게이팅되는 잔기를 갖는 폴리알킬렌 글리콜
JP2005526151A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2003210564A1 (en) Polyalkylene glycol with moiety for conjugating biologically active compound
US20170049904A1 (en) Polyalkylene polymer compounds and uses thereof
HK1224185B (en) Polyalkylene polymer compounds and uses thereof
HK1143553B (en) Polyalkylene glycol with moiety for conjugating biologically active compound
HK1072721B (en) Polyalkylene polymer compounds and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20040719

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080115

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20090915

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20100325

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20100609

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20100609

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20130524

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20130524

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20140527

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20140527

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20150526

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20150526

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20160527

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20160527

Start annual number: 7

End annual number: 7

A101 Application to extend term of patent right by permit
PA0101 Application to register extension of term of patent right by permit, etc.

Patent event date: 20161011

Patent event code: PA01011R01D

Comment text: Application to Register Extension of Term of Patent Right by Permit, etc.

FPAY Annual fee payment

Payment date: 20170529

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20170529

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20190508

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20190508

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20210517

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20230717

Termination category: Expiration of duration